International Strategies for Tropical Disease Treatments - Experiences with Praziquantel - EDM Research Series No. 026
(1998; 113 pages) View the PDF document
Table of Contents
View the documentAbstract
View the documentAcknowledgments
View the documentInformation on authors
View the documentExchange rates used in the report
Open this folder and view contentsChapter 1: Policies for praziquantel*
Open this folder and view contentsChapter 2: Bayer & E. Merck: Discovery and development of praziquantel*
Open this folder and view contentsChapter 3: Shin Poong Pharmaceutical Co.: Process development in the Republic of Korea*
Open this folder and view contentsChapter 4: The Egyptian International Pharmaceutical Industries Co.: Praziquantel formulation*
Open this folder and view contentsChapter 5: The international supply of praziquantel*
Close this folderChapter 6: Demand for praziquantel and national distribution*
View the documentThe demand for praziquantel
View the documentNational distribution of praziquantel
View the documentReferences
Open this folder and view contentsChapter 7: Prices and production costs of praziquantel*
View the documentOther documents in the DAP Research Series
View the documentDAP Research Series No. 26
 

Chapter 6: Demand for praziquantel and national distribution*

* By Michael R. Reich and Ramesh Govindaraj, with assistance from John Norris, Christopher Mast, and Agnes Brinkmann.

This chapter provides an assessment of the global demand for praziquantel, and describes national distribution of the drug in several developing countries. The section on demand focuses on the striking gap between the high potential demand for the drug (as evidenced by the prevalence of schistosomiasis in developing countries), and its limited supply by the existing producers and formulators of the drug. The chapter also discusses the impact of praziquantel’s high cost on the operation of schistosomiasis control programmes. The section on distribution of the drug discusses: the role of international agencies and bilateral aid organizations in assisting national schistosomiasis control programmes; the role of the private market in ensuring the availability of the drug in developing countries; and the role and success of national schistosomiasis programmes (using the example of Mali) in making the drug available to people afflicted by the disease.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: March 20, 2014